By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Biotechnology. According to news reporting originating from Minneapolis, Minnesota, by NewsRx correspondents, research stated, "Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Although some promising advances have been made, the immune response stimulated as a result of immunotherapeutic protocols has been inefficient at complete tumor elimination, primarily due to our lack of understanding of the necessary effector functions of the immune system."
Our news editors obtained a quote from the research from the University of Minnesota, "We previously demonstrated that a tumor lysate vaccine/Fc-OX40L therapy is capable of inducing enhanced survival and tumor elimination in the GL261 mouse glioma model. The following experiments were performed to determine the mechanism(s) of action of this therapy that elicits a potent antitumor immune response. The evidence subsequently outlined indicates a CD8(+) T cell-independent and CD4(+) T cell-, NK cell-, and B cell-dependent means of prolonged survival. CD8(+) T cell-independent tumor clearance is surprising considering the current focus of many cancer immunotherapy protocols."
According to the news editors, the research concluded: "These results provide evidence for CD8(+) T cell-independent means of antitumor response and should lead to additional examination of the potential manipulation of this mechanism for future treatment strategies."
For more information on this research see: CD8(+) T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma. Journal of Immunology, 2014;192(1):224-233. Journal of Immunology can be contacted at: Amer Assoc Immunologists, 9650 Rockville Pike, Bethesda, MD 20814, USA. (The American Association of Immunologists - www.aai.org; Journal of Immunology - www.jimmunol.org)
The news editors report that additional information may be obtained by contacting K.A. Murphy, University of Minnesota, Dept. of Neurosurg, Minneapolis, MN 55455, United States. Additional authors for this research include J.R. Erickson, C.S. Johnson, C.E. Seiler, J. Bedi, P.S. Hu, G.E. Pluhar, A.L. Epstein and J.R. Ohlfest (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Minnesota, Treatment, Minneapolis, Vaccination, Immunization, United States, Immunotherapy, Immunomodulation, Pre-Trial Research, Public Health Practice, North and Central America, Clinical Trials and Studies, Communicable Disease Control, Environment and Public Health
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC